These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24752253)

  • 1. Unacceptably high error rates in Vitek 2 testing of cefepime susceptibility in extended-spectrum-β-lactamase-producing Escherichia coli.
    Rhodes NJ; Richardson CL; Heraty R; Liu J; Malczynski M; Qi C; Scheetz MH
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3757-61. PubMed ID: 24752253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime.
    Jang W; Park YJ; Park KG; Yu J
    J Antimicrob Chemother; 2013 Oct; 68(10):2282-5. PubMed ID: 23671215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species.
    Kohner PC; Robberts FJ; Cockerill FR; Patel R
    J Clin Microbiol; 2009 Aug; 47(8):2419-25. PubMed ID: 19494061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the NCCLS extended-spectrum beta-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE.
    Tenover FC; Raney PM; Williams PP; Rasheed JK; Biddle JW; Oliver A; Fridkin SK; Jevitt L; McGowan JE;
    J Clin Microbiol; 2003 Jul; 41(7):3142-6. PubMed ID: 12843054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime.
    Pires J; Taracila M; Bethel CR; Doi Y; Kasraian S; Tinguely R; Sendi P; Bonomo RA; Endimiani A
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7483-8. PubMed ID: 26392491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypes and cephalosporin susceptibility in extended-spectrum beta-lactamase producing enterobacteriaceae in the community.
    Maina D; Revathi G; Kariuki S; Ozwara H
    J Infect Dev Ctries; 2012 Jun; 6(6):470-7. PubMed ID: 22706188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
    Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
    Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria.
    Kang CI; Cha MK; Kim SH; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
    Int J Antimicrob Agents; 2014 May; 43(5):456-9. PubMed ID: 24690213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
    Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
    Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of β-Lactamase Producing Escherichia coli from Retail Meat in Turkey.
    Pehlivanlar Önen S; Aslantaş Ö; Şebnem Yılmaz E; Kürekci C
    J Food Sci; 2015 Sep; 80(9):M2023-9. PubMed ID: 26256548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.
    Maglio D; Ong C; Banevicius MA; Geng Q; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1941-7. PubMed ID: 15155182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular characteristics of cefepime-susceptible Escherichia coli and Klebsiella spp. isolates with a positive β-lactamase screening test result but negative confirmation.
    Hu F; Wu W; Ye X; Xu X; Zhu D
    Eur J Clin Microbiol Infect Dis; 2010 Oct; 29(10):1297-9. PubMed ID: 20549530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The occurrence of ESBL-producing Escherichia coli carrying aminoglycoside resistance genes in urinary tract infections in Saudi Arabia.
    Alyamani EJ; Khiyami AM; Booq RY; Majrashi MA; Bahwerth FS; Rechkina E
    Ann Clin Microbiol Antimicrob; 2017 Jan; 16(1):1. PubMed ID: 28061852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Investigation of beta-lactamase genes and clonal relationship among the extended-spectrum beta-lactamase producing nosocomial Escherichia coli isolates].
    Görgeç S; Kuzucu Ç; Otlu B; Yetkin F; Ersoy Y
    Mikrobiyol Bul; 2015 Jan; 49(1):15-25. PubMed ID: 25706727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short communication: Bovine mastitis caused by a multidrug-resistant, mcr-1-positive (colistin-resistant), extended-spectrum β-lactamase-producing Escherichia coli clone on a Greek dairy farm.
    Filioussis G; Kachrimanidou M; Christodoulopoulos G; Kyritsi M; Hadjichristodoulou C; Adamopoulou M; Tzivara A; Kritas SK; Grinberg A
    J Dairy Sci; 2020 Jan; 103(1):852-857. PubMed ID: 31733863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
    Mohanty S; Gaind R; Ranjan R; Deb M
    J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010-2011.
    Zykov IN; Sundsfjord A; Småbrekke L; Samuelsen Ø
    Infect Dis (Lond); 2016 Feb; 48(2):99-107. PubMed ID: 26414659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, Antibiogram, and Resistance Profile of Extended-Spectrum β-Lactamase-Producing
    Gundran RS; Cardenio PA; Salvador RT; Sison FB; Benigno CC; Kreausukon K; Pichpol D; Punyapornwithaya V
    Microb Drug Resist; 2020 Feb; 26(2):160-168. PubMed ID: 31532307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefepime versus extended spectrum β-lactamase-producing Enterobacteriaceae.
    Nogueira Kda S; Daur AV; Reason IT; Gales AC; Costa LM
    Braz J Infect Dis; 2011; 15(2):167-9. PubMed ID: 21503406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.